TROY is a Marker and Therapeutic Target in Melanoma and other Cancers

The Portal is a joint project of MATTO and the MTTC. The development and implementation of the portal has been paid for by the MTTC, Beth Israel Deaconess Medical Center, Boston Biomedical Research Institute, Boston University, Brandeis University, Caritas St. Elizabeth's Medical Center, Boston Children's Hospital, Dana Farber Cancer Institute, Harvard University, Joslin Diabetes Center, Massachusetts Eye and Ear Infirmary, Massachusetts General Hospital, McLean Hospital, Northeastern University, The Schepens Eye Research Institute, and Tufts University.

Intellectual Property

ID:		01-58
IP Type:		Licensable Technology
Title:		TROY is a Marker and Therapeutic Target in Melanoma and other Cancers
Inventor:		Spanjaard, Remco A.
Summary:		Even though melanoma represents only 4% of the total number of cases, it is responsible for 79% of all cancer deaths. ? The inventor found that melanomatissue samples stained positive for this newly identified extracellular target, while normal melanocytes (as well as keratinocytes and fibroblasts are completely negative.The correlation of expression of this protein could be used as a marker or as a novel therapeutic target for metastatic melanoma
Tech Type:		Diagnostics/Biomarkers
URL:		http://ctf-fmfe.bu.edu/BU0158.pdf
Contact:		April Effort, chofmann@bu.edu, 617 353 7631
Organization:		Boston University

Display all intellectual properties for Spanjaard, Remco A.
Display all intellectual properties for Boston University